WHO Draft Guidelines On Biosimilar MAbs: Extrapolation 'A Goal' Of Development Program
This article was originally published in SRA
The World Health Organization has launched a public consultation on proposed draft guidelines1 for the evaluation of biosimilar monoclonal antibodies (MAbs) to complement its existing 2009 guidance on "similar biotherapeutic products" (SBPs)2. Comments are invited until April 5.
Register for our free email digests: